Important Note Regarding the September 11, 2017 Press Release Announcing Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma

You are now leaving Investor.Regeneron.com. The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.

Continue

Release Details

Important Note Regarding the September 11, 2017 Press Release Announcing Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma